Literature DB >> 9234749

Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds.

A Egan1, M Waterfall, M Pinder, A Holder, E Riley.   

Abstract

We have investigated the relationship between cellular and humoral immune responses to defined epitopes of the C terminus of merozoite surface protein 1 (MSP-1) of the human malaria parasite, Plasmodium falciparum, in immune blood donors. Sera from almost all donors contained antibodies to the 33-kDa processing product of the MAD20 allele of MSP-1 (MSP-1(33)), but these antibodies did not cross-react with the equivalent sequence of the Wellcome allele. In contrast, T-cell responses to MSP-1(33) are directed towards epitopes that are conserved between the two allelic families. Only 50% of adult blood donors possessed antibodies which recognized the 19-kDa processing product of MSP-1 (MSP-1(19)). These antibodies predominantly recognized conserved epitopes involving both of the constituent epidermal growth factor-like domains of MSP-1(19). T-cell responses were found in only 26% (for recombinant proteins) or 44% (for synthetic peptides) of donors and were directed mainly at dimorphic sequences of the protein. There was no obvious association, at an individual level, between the presence of antibodies and the detection of T-cell proliferative or gamma interferon responses, suggesting that the T cells identified in this manner are not providing significant levels of help to B cells. T-cell responses to reduced recombinant proteins and linear peptides were more prevalent than responses to disulfide-bonded proteins, suggesting that the complex disulfide-bonded structure of native MSP-1(19) may inhibit antigen processing or presentation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234749      PMCID: PMC175426          DOI: 10.1128/iai.65.8.3024-3031.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum.

Authors:  K Tanabe; M Mackay; M Goman; J G Scaife
Journal:  J Mol Biol       Date:  1987-05-20       Impact factor: 5.469

2.  Immunization against Plasmodium falciparum with recombinant polypeptides produced in Escherichia coli.

Authors:  A A Holder; R R Freeman; S C Nicholls
Journal:  Parasite Immunol       Date:  1988-11       Impact factor: 2.280

3.  Mortality and morbidity from malaria among children in a rural area of The Gambia, West Africa.

Authors:  B M Greenwood; A K Bradley; A M Greenwood; P Byass; K Jammeh; K Marsh; S Tulloch; F S Oldfield; R Hayes
Journal:  Trans R Soc Trop Med Hyg       Date:  1987       Impact factor: 2.184

4.  Third form of the precursor to the major merozoite surface antigens of Plasmodium falciparum.

Authors:  M G Peterson; R L Coppel; M B Moloney; D J Kemp
Journal:  Mol Cell Biol       Date:  1988-06       Impact factor: 4.272

5.  Selective recognition of malaria antigens by human serum antibodies is not genetically determined but demonstrates some features of clonal imprinting.

Authors:  R R Taylor; A Egan; D McGuinness; A Jepson; R Adair; C Drakely; E Riley
Journal:  Int Immunol       Date:  1996-06       Impact factor: 4.823

6.  Monoclonal antibody two-site ELISA for human IFN-gamma. Adaptation for determinations in human serum or plasma.

Authors:  G Andersson; H P Ekre; G Alm; P Perlmann
Journal:  J Immunol Methods       Date:  1989-12-20       Impact factor: 2.303

7.  Major surface antigen gene of a human malaria parasite cloned and expressed in bacteria.

Authors:  R Hall; J E Hyde; M Goman; D L Simmons; I A Hope; M Mackay; J Scaife; B Merkli; R Richle; J Stocker
Journal:  Nature       Date:  1984 Sep 27-Oct 3       Impact factor: 49.962

8.  Epitopes recognized by human T cells map within the conserved part of the GP190 of P. falciparum.

Authors:  A Crisanti; H M Müller; C Hilbich; F Sinigaglia; H Matile; M McKay; J Scaife; K Beyreuther; H Bujard
Journal:  Science       Date:  1988-06-03       Impact factor: 47.728

9.  Nonpolymorphic regions of p190, a protein of the Plasmodium falciparum erythrocytic stage, contain both T and B cell epitopes.

Authors:  F Sinigaglia; B Takacs; H Jacot; H Matile; J R Pink; A Crisanti; H Bujard
Journal:  J Immunol       Date:  1988-05-15       Impact factor: 5.422

10.  Expression of hybrid malaria antigens in insect cells and their engineering for correct folding and secretion.

Authors:  V F Murphy; W C Rowan; M J Page; A A Holder
Journal:  Parasitology       Date:  1990-04       Impact factor: 3.234

View more
  50 in total

1.  In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system.

Authors:  Alan L Y Pang; Caryn N Hashimoto; Leslie Q Tam; Z Q Meng; George S N Hui; Walter K K Ho
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

2.  Antibody responses and avidity of naturally acquired anti-Plasmodium vivax Duffy binding protein (PvDBP) antibodies in individuals from an area with unstable malaria transmission.

Authors:  Sedigheh Zakeri; Laleh Babaeekhou; Akram Abouie Mehrizi; Maryam Abbasi; Navid Dinparast Djadid
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

3.  Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria.

Authors:  D Dodoo; T G Theander; J A Kurtzhals; K Koram; E Riley; B D Akanmori; F K Nkrumah; L Hviid
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

4.  Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88.

Authors:  John T Bates; Aaron H Graff; James P Phipps; Jason M Grayson; Steven B Mizel
Journal:  J Immunol       Date:  2011-04-22       Impact factor: 5.422

5.  Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.

Authors:  Puneet K Gupta; Paushali Mukherjee; Shikha Dhawan; Alok K Pandey; Suman Mazumdar; Deepak Gaur; S K Jain; Virander S Chauhan
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

6.  Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli.

Authors:  Suraksha Sachdeva; Gul Ahmad; Pawan Malhotra; Paushali Mukherjee; V S Chauhan
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

7.  Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4.

Authors:  James M Burns; Patrick R Flaherty; Payal Nanavati; William P Weidanz
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  Identification of a polyclonal B-cell activator in Plasmodium falciparum.

Authors:  Daria Donati; Li Ping Zhang; Arnaud Chêne; Qijun Chen; Kirsten Flick; Maja Nyström; Mats Wahlgren; Maria Teresa Bejarano
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

9.  Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection.

Authors:  Christian M F Okafor; Chiaka I Anumudu; Yusuf O Omosun; Chairat Uthaipibull; Idowu Ayede; Henrietta O Awobode; Alex B Odaibo; Jean Langhorne; Anthony A Holder; Roseangela I Nwuba; Marita Troye-Blomberg
Journal:  Malar J       Date:  2009-11-23       Impact factor: 2.979

10.  Antibody-dependent transplacental transfer of malaria blood-stage antigen using a human ex vivo placental perfusion model.

Authors:  Karen May; Markus Grube; Indu Malhotra; Carole A Long; Sanjay Singh; Kishor Mandaliya; Werner Siegmund; Christoph Fusch; Henning Schneider; Christopher L King
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.